Aerobic glycolysis: A novel target in kidney cancer

Expert Review of Anticancer Therapy

Volumn 13, Issue 6, 2013, Pages 711-719

  Shuch, Brian ^a   Linehan, W Marston ^a   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

glycolysis; kidney cancer; Krebs cycle; metabolism; Warburg effect

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; ERLOTINIB; GLUCOSE; GLUTAMINASE; HEMOXYGENASE; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; MAMMALIAN TARGET OF RAPAMYCIN; OXYGENASE; PHOSPHATE DEHYDROGENASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ADVANCED CANCER; AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; CANCER CLASSIFICATION; CARCINOGENESIS; CITRIC ACID CYCLE; COMPLEX II DEFICIENCY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ENERGY METABOLISM; GENE; GENE MUTATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HEREDITARY LEIOMYOMATOSIS KIDNEY CARCINOMA; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MACROMOLECULE; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PKM2 GENE; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; CITRIC ACID CYCLE; GLUCOSE; GLYCOLYSIS; HEXOKINASE; HUMANS; KIDNEY NEOPLASMS; LEIOMYOMATOSIS; MOLECULAR TARGETED THERAPY; PYRUVATE KINASE; SUCCINATE DEHYDROGENASE;

EID: 84879365771     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.57     Document Type: Review

References (82)

1. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, GA, USA (2010).
2. Linehan WM. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J. Urol. 170, 593 (2003).
3. Singer EA, Bratslavsky G, Linehan WM, Srinivasan R. Targeted therapies for non-clear renal cell carcinoma. Target. Oncol. 5(2), 119-129 (2010).
4. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7(5), 277-285 (2010).
5. Warburg O. On respiratory impairment in cancer cells. Science 124(3215), 269-270 (1956).
6. Warburg O. The prime cause and prevention of cancer. Presented at: the 17th Annual Lindau Nobel Laureate Meetings. Lindau, Germany (1967).
7. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J. Natl Cancer Inst. 96(24), 1805-1806 (2004). (Pubitemid 40081310)
8. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF1? in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394(6692), 485-490 (1998). (Pubitemid 28373960)
9. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 94(15), 8104-8109 (1997). (Pubitemid 27343784)
10. Elstrom RL, Bauer DE, Buzzai M et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64(11), 3892-3899 (2004). (Pubitemid 38697301)
11. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3(3), 177-185 (2006).
12. Shim H, Dolde C, Lewis BC et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl Acad. Sci. USA 94(13), 6658-6663 (1997). (Pubitemid 27281920)
13. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxiainducible factor 1? (HIF1?) and HIF-2? in hypoxic gene regulation. Mol. Cell. Biol. 23(24), 9361-9374 (2003). (Pubitemid 37499822)
14. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7(1), 85-90 (1994). (Pubitemid 24232386)
15. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91(21), 9700-9704 (1994). (Pubitemid 24311875)
16. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112), 1317-1320 (1993). (Pubitemid 23231974)
17. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733), 271-275 (1999). (Pubitemid 29246458)
18. Chen C, Pore N, Behrooz A et al. Regulation of glut1 mRNA by hypoxiainducible factor-1. Interaction between H-ras and hypoxia. J. biol. chem. 276, 9519 (2001).
19. Kim JW, Zeller KI, Wang Y et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol. Cell. Biol. 24(13), 5923-5936 (2004). (Pubitemid 38787976)
20. Osthus RC, Shim H, Kim S et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 275(29), 21797-21800 (2000). (Pubitemid 30621745)
21. Mayr JA, Meierhofer D, Zimmermann F et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin. Cancer Res. 14(8), 2270-2275 (2008). (Pubitemid 351551057)
22. Selvanayagam P, Rajaraman S. Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma. Lab. Invest. 74(3), 592-599 (1996). (Pubitemid 26105720)
23. Horton TM, Petros JA, Heddi A et al. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer 15(2), 95-101 (1996). (Pubitemid 26048409)
24. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15(21), 6479-6483 (2009).
25. Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J. Med. Genet. 43(6), 523-526 (2006). (Pubitemid 43927328)
26. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am. J. Surg. Pathol. 31(10), 1578-1585 (2007). (Pubitemid 47482473)
27. Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm. Venereol. 53(5), 409-416 (1973).
28. Launonen V, Vierimaa O, Kiuru M et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl Acad. Sci. USA 98(6), 3387-3392 (2001). (Pubitemid 32220855)
29. Alam NA, Bevan S, Churchman M et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am. J. Hum. Genet. 68(5), 1264-1269 (2001). (Pubitemid 32424424)
30. Tong WH, Sourbier C, Kovtunovych G et al. The glycolytic shift in fumaratehydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 20(3), 315-327 (2011).
31. Grubb RL 3rd, Franks ME, Toro J et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J. Urol. 177, 2074 (2007).
32. Astuti D, Latif F, Dallol A et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69(1), 49-54 (2001). (Pubitemid 32614017)
33. Baysal BE, Ferrell RE, Willett-Brozick JE et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287(5454), 848-851 (2000). (Pubitemid 30084326)
34. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet. 26(3), 268-270 (2000).
35. Ricketts C, Woodward ER, Killick P et al. Germline SDHB mutations and familial renal cell carcinoma. J. Natl Cancer Inst. 100(17), 1260-1262 (2008).
36. Vanharanta S, Buchta M, McWhinney SR et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74(1), 153-159 (2004). (Pubitemid 38085246)
37. Bratslavsky G, Linehan WM. Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat. Rev. Urol. 7(5), 267-275 (2010).
38. Ricketts CJ, Shuch B, Vocke CD et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J. Urol. 188(6), 2063-2071 (2012).
39. Gill AJ, Pachter NS, Chou A et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am. J. Surg. Pathol. 35(10), 1578-1585 (2011).
40. Isaacs JS, Jung YJ, Mole DR et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8(2), 143-153 (2005). (Pubitemid 41132743)
41. Selak MA, Armour SM, MacKenzie ED et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-? prolyl hydroxylase. Cancer Cell 7(1), 77-85 (2005). (Pubitemid 40126384)
42. Abou Youssif T, Fahmy MA, Koumakpayi IH et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117(2), 290-300 (2011).
43. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol. 16(6), 928-933 (2005). (Pubitemid 40903919)
44. Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109(11), 2257-2267 (2007). (Pubitemid 46801555)
45. Baba M, Hong SB, Sharma N et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl Acad. Sci. USA 103(42), 15552-15557 (2006). (Pubitemid 44625630)
46. Hasumi Y, Baba M, Ajima R et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc. Natl Acad. Sci. USA 106(44), 18722-18727 (2009).
47. Sudarshan S, Sourbier C, Kong HS et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1? stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell. Biol. 29(15), 4080-4090 (2009).
48. Finley LW, Carracedo A, Lee J et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1a destabilization. Cancer Cell 19(3), 416-428 (2011).
49. Shi DY, Xie FZ, Zhai C, Stern JS, Liu Y, Liu SL. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells. Mol. Cancer 8, 32 (2009).
50. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev. Cancer 3(3), 193-202 (2003). (Pubitemid 37328871)
51. Smith EH, Janknecht R, Maher LJ 3rd. Succinate inhibition of ?-ketoglutaratedependent enzymes in a yeast model of paraganglioma. Hum. Mol. Genet. 16(24), 3136-3148 (2007). (Pubitemid 350131331)
52. Pollard PJ, Spencer-Dene B, Shukla D et al. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11(4), 311-319 (2007). (Pubitemid 46518311)
53. Adam J, Hatipoglu E, O'Flaherty L et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20(4), 524-537 (2011).
54. Ooi A, Wong JC, Petillo D et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20(4), 511-523 (2011).
55. Mitsuishi Y, Taguchi K, Kawatani Y et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22(1), 66-79 (2012).
56. Chan DA, Sutphin PD, Nguyen P et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3(94), 94ra70 (2011).
57. Noguchi T, Inoue H, Tanaka T. The M1-and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 261(29), 13807-13812 (1986). (Pubitemid 17196407)
58. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 15(4), 300-308 (2005). (Pubitemid 41058775)
59. Christofk HR, Vander Heiden MG, Harris MH et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452(7184), 230-233 (2008). (Pubitemid 351380249)
60. Luo W, Hu H, Chang R et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145(5), 732-744 (2011).
61. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res. 22(1A), 311-318 (2002). (Pubitemid 34475318)
62. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43(7), 969-980 (2011).
63. Christofk HR, Vander Heiden MG, Wu N et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181 (2008).
64. Vander Heiden MG, Christofk HR, Schuman E et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 79(8), 1118-1124 (2010).
65. Brown J. Effects of 2-deoxyglucose on carbohydrate metabolism: review of the literature and studies in the rat. Metab. Clin. Exp. 11, 1098-1112 (1962).
66. Yamasaki T, Tran TA, Oz OK et al. Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat. Rev. Urol. 8(3), 165-171 (2011).
67. Zhong D, Liu X, Schafer-Hales K et al. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol. Cancer Ther. 7(4), 809-817 (2008). (Pubitemid 351551034)
68. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv. Drug Deliv. Rev. 61(14), 1250-1275 (2009).
69. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9(6), 425-434 (2006). (Pubitemid 43832190)
70. Xie H, Valera VA, Merino MJ et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther. 8(3), 626-635 (2009).
71. DeBerardinis RJ, Mancuso A, Daikhin E et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104(49), 19345-19350 (2007).
72. Frezza C, Zheng L, Folger O et al. Hem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477(7363), 225-228 (2011).
73. Mullen AR, Wheaton WW, Jin ES et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481(7381), 385-388 (2012).
74. Wise DR, DeBerardinis RJ, Mancuso A et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl Acad. Sci. USA 105(48), 18782-18787 (2008).
75. Wang JB, Erickson JW, Fuji R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18(3), 207-219 (2010).
76. Seltzer MJ, Bennett BD, Joshi AD et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70(22), 8981-8987 (2010).
77. Cheng T, Sudderth J, Yang C et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl Acad. Sci. USA 108(21), 8674-8679 (2011).
78. Upton MP, Parker RA, Youmans A et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. 28, 488-495 (2005). (Pubitemid 41232570)
79. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J. Clin. Oncol. 20(9), 2376-2381 (2002). (Pubitemid 34441667)
80. Plimack E, Jonasch E, Bekele B et al. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm Phase II study. J. Clin. Oncol. 28, 15s (2010).
81. Pan C, Hussey M, Lara P et al. Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): final results from Southwest Oncology Group study 0317. J. Clin. Oncol. 26, Abstract 5051 (2008).
82. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23(31), 7889-7896 (2005). (Pubitemid 46657387)